Next Article in Journal
Structure–Activity Relationships of Cationic Lipidoids against Escherichia coli
Next Article in Special Issue
Antimicrobial Susceptibility from a One Health Perspective Regarding Porcine Escherichia coli from Bavaria, Germany
Previous Article in Journal
Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
Previous Article in Special Issue
Fecal Carriage of Extended-Spectrum β-Lactamase-/AmpC-Producing Escherichia coli in Pet and Stray Cats
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 8
10.3390/antibiotics12081298
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis Isolated from Pigs in Hungary between 2018 and 2021

by
Zoltán Somogyi
1,2,*,
Patrik Mag
1,2,
Réka Simon
1,
Ádám Kerek
1,2,
László Makrai
2,3,
Imre Biksi
4,5 and
Ákos Jerzsele
1,2
1
Department of Pharmacology and Toxicology, University of Veterinary Medicine, István Str. 2., H-1078 Budapest, Hungary
2
National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary Public Health and Food Chain Safety, University of Veterinary Medicine, H-1078 Budapest, Hungary
3
Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, István Str. 2., H-1078 Budapest, Hungary
4
Department of Pathology, University of Veterinary Medicine, István Str. 2., H-1078 Budapest, Hungary
5
SCG Diagnostics Ltd., HU-2437 Délegyháza, Hungary
*
Author to whom correspondence should be addressed.
Antibiotics 2023, 12(8), 1298; https://doi.org/10.3390/antibiotics12081298
Submission received: 21 June 2023 / Revised: 13 July 2023 / Accepted: 17 July 2023 / Published: 8 August 2023
(This article belongs to the Special Issue Epidemiology, Impact and Mitigation of Antimicrobial Resistance in Veterinary Medicine, 2nd Volume)
Browse Figure
Versions Notes

Abstract

:
Porcine respiratory disease complex (PRDC) has been a major animal health, welfare, and economic problem in Hungary; therefore, great emphasis should be put on both the prevention and control of this complex disease. As antibacterial agents are effective tools for control, antibiotic susceptibility testing is indispensable for the proper implementation of antibacterial therapy and to prevent the spread of resistance. The best method for this is to determine the minimum inhibitory concentration (MIC) by the broth microdilution method. In our study, we measured the MIC values of 164 Actinobacillus pleuropneumoniae, 65 Pasteurella multocida, and 118 Streptococcus suis isolates isolated from clinical cases against the following antibacterial agents: amoxicillin, ceftiofur, cefquinome, oxytetracycline, doxycycline, tylosin, tilmicosin, tylvalosin, tulathromycin, lincomycin, tiamulin, florfenicol, colistin, enrofloxacin, and sulfamethoxazole-trimethoprim. Outstanding efficacy against A. pleuropneumoniae isolates was observed with ceftiofur (100%) and tulathromycin (100%), while high levels of resistance were observed against cefquinome (92.7%) and sulfamethoxazole-trimethoprim (90.8%). Ceftiofur (98.4%), enrofloxacin (100%), florfenicol (100%), and tulathromycin (100%) were found to be highly effective against P. multocida isolates, while 100% resistance was detected against the sulfamethoxazole-trimethoprim combination. For the S. suis isolates, only ceftiofur (100%) was not found to be resistant, while the highest rate of resistance was observed against the sulfamethoxazole-trimethoprim combination (94.3%). An increasing number of studies report multi-resistant strains of all three pathogens, making their monitoring a high priority for animal and public health.

1. Introduction

Porcine Respiratory Disease Complex (PRDC) is most commonly found in weaning and weaning-to-finishing pigs and is a complex disease, i.e., in most cases caused by multiple pathogens or facultative pathogens. The primary pathogenic agents of PRDC are Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, and Bordetella bronchiseptica, as well as viruses causing various respiratory pathologies [1,2]. Pasteurella multocida, Streptococcus suis, Glässerella parasuis, and Salmonella Choleraesuis are usually considered secondary pathogens [3]. These primary and secondary pathogens together form PRDC, whose severity gradually increases until it is out of control [4,5,6].
The continuous monitoring of antibacterial agents is a very important task, as it is not only of animal health, animal welfare, and economic importance but also of paramount public health importance. The European Committee on Antimicrobial Susceptibility Testing [7] plays an important role in this, not only by testing pathogens coming from public health but also by testing pathogens of animal origin. This includes the antibiotic susceptibility of bacteria involved in the development of PRDC. There are further proposals for the establishment of an EU-wide antimicrobial resistance (AMR) monitoring system [8,9].
Determining the minimum inhibitory concentration (MIC) of PRDC-causing bacteria not only allows us to measure the prevalence of different resistant strains but also provides a quantitative result that helps determine the exact antibacterial therapy. The MIC value can also be used to perform pharmacokinetic/pharmacodynamic analysis, which is important in determining the dose of antibacterial agents. The dose helps select the appropriate route of drug administration and the frequency of antibacterial agent use, i.e., the time interval between two administrations [10,11]. There have been fewer studies on the antibiotic susceptibility of PRDC pathogens in the last five years than in the early 2010s, which further strengthens the need for this [12].
In the present study, we investigated the antibiotic susceptibility of three bacterial species most frequently responsible for respiratory tract infections in pigs in Hungary. Actinobacillus pleuropneumoniae, Pasteurella multocida, and Streptococcus suis strains were evaluated for their susceptibility to amoxicillin, ceftiofur, cefquinome, oxytetracycline, doxycycline, tylosin, tilmicosin, tylvalosin, tulathromycin, lincomycin, tiamulin, florfenicol, colistin, enrofloxacin, and sulfamethoxazole-trimethoprim.
Amoxicillin, ceftiofur, and cefquinome belong to the beta-lactam group of antibiotics that are used extensively in pig medicine. According to the EMA classification, amoxicillin is one of the antimicrobials that should be the first choice in veterinary medicine, thus reducing the use of more important public health agents such as ceftiofur and cefquinome [13,14,15,16,17].
Oxytetracycline, doxycycline, and sulfamethoxazole-trimethoprim, like amoxicillin, should be prioritised in animal health. Unfortunately, antimicrobial resistance to these agents is the highest. For this reason, it is of paramount importance to assess the antibiotic susceptibility of pathogenic bacteria prior to the use of these products [14,18,19,20,21].
Macrolides (tylosin, tilmicosin, tylvalosin, and tulathromycin), lincomycin, tiamulin, and florfenicol are some of the most important agents in the treatment of respiratory tract infections in pigs, so the assessment of resistance to them is very important in pig medicine. They are also of public health importance, as cross-resistance between macrolides and oxazolidinones (linezolid), which are important for public health, can occur [14,18,22,23,24,25,26,27,28,29,30,31].
Colistin is a less important antibacterial agent in respiratory diseases of pigs, but its public health importance is paramount, so it is important to confirm or exclude the presence of resistance to it in all Gram-negative pathogens [14,32,33,34].
The susceptibility of bacteria to enrofloxacin is important at both the public health and pig health levels, as it is still commonly used in most countries, despite its public health importance being as high as that of colistin [14,35,36,37,38,39,40].

2. Results

2.1. Susceptibility of Actinobacillus pleuropneumoniae Isolates

The susceptibility of 164 A. pleuropneumoniae clinical isolates collected by us was tested against 15 antibacterial agents. The clinical breakpoint and epidemiological cut-off value for MIC set by the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are available for the following antibacterial agents: amoxicillin, ceftiofur, cefquinome, oxytetracycline, tilmicosin, tulathromycin, tiamulin, florfenicol, enrofloxacin, and sulfamethoxazole-trimethoprim [7,41]. Thus, sensitivity was only determined for these agents. High susceptibility to ceftiofur (100%), tilmicosin (95.7%), tulathromycin (100%), and florfenicol (98.8%) was observed for the tested isolates [41], with low MIC90 values (0.125 µg/mL, 8 µg/mL, 16 µg/mL, and 4 µg/mL, respectively). In contrast, a lower percentage of the tested isolates were sensitive to amoxicillin (64.0%), oxytetracycline (44.4%), tiamulin (70.5%), and enrofloxacin (47.5%) [41]. For amoxicillin, oxytetracycline, and tiamulin, MIC90 values of 64 µg/mL were determined in all cases, while for enrofloxacin, the MIC90 value was 4 µg/mL. Only 7.3% and 9.8% of the isolates were found to be sensitive to cefquinome and sulfamethoxazole-trimethoprim, respectively, taking into account the epidemiological cut-off values set by EUCAST [7]. These agents were associated with MIC90 values of 0.25 µg/mL and 64 µg/mL. For tylvalosin, the MIC values were 64 µg/mL for both MIC50 and MIC90. For tylosin and lincomycin, similar MIC values were observed (MIC50 32 µg/mL and MIC90 64 µg/mL). For the other drugs, MIC values were the following: for doxycycline, MIC50 was 1 µg/mL, MIC90 was 16 µg/mL, and for colistin, MIC50 was 0.015 µg/mL, and MIC90 was 1 µg/mL. The susceptibility of A. pleuropneumoniae strains to the tested drugs is summarised in Table 1 and Table 2.
Comparing the susceptibility of the tested isolates with the clinical breakpoints defined by CLSI, 89 isolates (54.3%) did not show resistance to any antimicrobial agent. A total of 34 isolates (20.7%) showed resistance to only one antibiotic, while 17 isolates (10.4%) showed resistance to two antibiotics. A total of twenty-four isolates proved to be multidrug resistant (MDR), of which twenty-two isolates (13.4%) showed resistance to three antibiotics and two isolates (1.2%) showed resistance to four antibiotics (Figure 1).
In total, 13 AMR profiles were identified among A. pleuropneumoniae isolates. Of these, five profiles were identified where the isolates showed resistance to three or more antibiotics (MDR profiles). A total of 24 (14.6%) isolates belonged to these MDR profiles. Half of these isolates were in one profile (profile 1). Of the other half of the isolates, eight isolates were in profile two, two isolates were in profile three, and one isolate was in both profiles four and five (Table 3).

2.2. Susceptibility of Pasteurella multocida Isolates

The 65 P. multocida clinical isolates were tested for 12 antibacterial agents. Clinical breakpoints or epidemiological cut-off values defined by CLSI or EUCAST are available for most of the agents we tested [7,41]. Exceptions are tylosin and lincomycin, for which identical MIC50 (16 µg/mL) and MIC90 (32 µg/mL) values were determined, and colistin, for which lower MIC values were found compared to the two antibacterial agents (MIC50 0.03 µg/mL and MIC90 0.06 µg/mL). Compared to the CLSI clinical breakpoints and the EUCAST epidemiological cut-off values, doxycycline was found to be the least effective, with only 69.2% of P. multocida isolates being susceptible and a MIC90 of 2 µg/mL. For ceftiofur, tilmicosin, and tiamulin, >90% of the isolates were sensitive (MIC90 0.125 µg/mL, 8 µg/mL, and 16 µg/mL), and all isolates were sensitive for amoxicillin, tulathromycin, florfenicol, and enrofloxacin (MIC90 1 µg/mL, 0.5 µg/mL, 1 µg/mL, and 0.06 µg/mL). The susceptibility of P. multocida isolates to the tested agents is summarised in Table 4 and Table 5.

2.3. Susceptibility of Streptococcus suis Isolates

The susceptibility of 118 clinical isolates of S. suis to 11 antibacterial agents was determined. One hundred percent of the isolates were sensitive to ceftiofur, with a MIC90 of 1 µg/mL. For florfenicol, 75.4% of isolates (MIC90 8 µg/mL) and for enrofloxacin, 82.9% of isolates (MIC90 8 µg/mL) were sensitive. The S. suis isolates tested were highly resistant to the combination sulfamethoxazole-trimethoprim, with only 5.7% being sensitive and a MIC90 of 256 µg/mL. The MIC values of the other tested substances were variable. Amoxicillin had the lowest MIC value (MIC50 0.06 µg/mL and MIC90 4 µg/mL). Doxycycline had a MIC50 of 8 µg/mL and a MIC90 of 32 µg/mL. The MIC50 values for tylosin, tilmicosin, tulathromycin, and lincomycin differed (32 µg/mL, 8 µg/mL, 2 µg/mL, and 32 µg/mL, respectively), but their MIC90 values were the same (128 µg/mL). The sensitivity of the isolates to the tested drugs is summarised in Table 6 and Table 7.

3. Discussion

The continuous monitoring of antibacterial agents is an extremely important task for veterinarians, as it has not only a veterinary and economic purpose but is also beneficial for public health. Continuous monitoring of the susceptibility to antibacterial products used in food-producing farm animals helps us optimise therapeutic management and inhibit the spread of antimicrobial resistance. In order to reduce resistant strains of bacteria, Hungary has already tightened the conditions of antibiotic use [42], based on the European Union (EU) Directive 2001/82/EC [43], and from 8 January 2022, the stricter use of antibiotics has been regulated at EU level [44]. By monitoring the resistance profile of bacterial strains on livestock farms, we can successfully determine the antibacterial agents of choice at the herd level, further reducing the chance of selection of resistant strains.
In order to set clinical breakpoints at the national level to assist veterinarians working in livestock farms, it would be necessary to carry out harmonised susceptibility testing using the same methodology to determine the susceptibility of bacteria in different farms. The development of such a test method and the creation of a central database would be a valuable addition to national veterinary practice and, if harmonised at an international level, would open up new ways of combating resistant strains of bacteria. To implement the previous proposal, our research group applied for and won a grant to establish a National Laboratory for Animal Infectious Diseases, Antimicrobial Resistance, Veterinary Public Health, and Food Chain Safety, which will allow this work to be carried out.

3.1. Susceptibility of Actinobacillus pleuropneumoniae Isolates

The isolates of A. pleuropneumoniae we tested were 100% sensitive to ceftiofur and tulathromycin, which is in agreement with the previous literature [6,8,45,46,47,48]. However, 92.7% of the isolates we tested were resistant to cefquinome. Cefquinome is a frequently used antibacterial agent in the pig farming industry in Hungary. Unfortunately, the use of cefquinome may increase the chance of the selection of bacteria resistant to beta-lactam antibiotics [14,16,17]. Based on our results, it would be advisable to greatly reduce its use in animal health. This would presumably have positive results, both in animal health and in public health. To florfenicol, 98.8% of isolates were sensitive, and to tilmicosin, 95.7% of isolates were sensitive; the results are in agreement with the data previously published by others [6,8,45,46,47,48,49]. However, it was observed that while in previous studies more than 95% of the isolates were sensitive to tiamulin [6,8,46,48], only 70.5% of the isolates tested in our study were sensitive to this antibiotic. To amoxicillin, 64.0% of the isolates were sensitive, which is moderate compared to that observed by Vilaró et al. (72.2%) [48]. There is a divergent picture in the literature on the sensitivity of A. pleuropneumoniae isolates to tetracyclines. While in a Danish study by Holmer et al., 92.4% of isolates were sensitive to the antibacterial agent [8], only 76% of isolates were sensitive in a Czech Republic study by Kucerova et al. [46], and 70% of isolates were sensitive in a European monitoring programme by El Garch et al. [6]. In the Spanish survey by Gutiérrez-Martín et al., only 26.2% of the strains were sensitive to tetracyclines [49]. In the North American survey by Portis et al., less than 7.4% of the isolates were sensitive to tetracyclines [45], while in the North American survey by Sweeney et al., all strains were resistant [47]. A total of 44.4% of our isolates were sensitive, which is in line with what has been described previously in Central and Eastern Europe. For enrofloxacin, in most cases, more than 95% of strains showed sensitivity [6,45,47], with only Vilaró et al. describing a lower sensitivity (72.2%) [48]. In comparison, 47.5% of the isolates we collected were sensitive, which is strikingly low compared to previous results. The case is even more severe for the sulfamethoxazole-trimethoprim combination, where 90.8% of the isolates were resistant, while the same value in the literature is below 12% [6,48].
For doxycycline, our MIC values (MIC50 1 µg/mL and MIC90 16 µg/mL) were higher than previously reported by Vilaró et al. (MIC50 0.5 µg/mL and MIC90 4 µg/mL) [48] and Yuan et al. (MIC90 8 µg/mL) [50]. The same can be said for lincomycin, where the MIC50 and MIC90 of the isolates we collected were 32 µg/mL and 64 µg/mL, while values of 16 µg/mL and 32 µg/mL were reported in the literature for the same values [6,51]. For tylosin, the MIC90 of our isolates was the same as that reported in the El Garch et al. study (64 µg/mL) [6]. For colistin, MIC values were lower (MIC50 0.015 µg/mL and MIC90 1 µg/mL) than those reported in the Swiss study by Matter et al. (MIC50 1 µg/mL and MIC90 2 µg/mL) [52].
Based on these data, the most effective antibacterial agents for A. pleuropneumoniae infection will be ceftiofur and tulathromycin. Florfenicol and tilmicosin also have outstanding efficacy against the bacteria. Nationally, enrofloxacin and tiamulin have been shown to be less effective, so these antibiotics should only be used after sensitivity testing. The moderate susceptibility of amoxicillin and oxytetracycline is in line with the literature, while cefquinome and sulfamethoxazole-trimethoprim have been found to have high resistance in the national context and should be used only in exceptional cases after sensitivity testing.

3.2. Susceptibility of Pasteurella multocida Isolates

The P. multocida isolates we tested were all sensitive to amoxicillin, enrofloxacin, florfenicol, and tulathromycin. Similar results can be found in the literature for all four antibacterial agents [6,47,48,53], but less pronounced susceptibilities have been reported for enrofloxacin and florfenicol (93.1% [54] and 81.5% [53]). Our result for ceftiofur, where 98.4% of isolates were sensitive, is similar to that described by Oh et al. [53], but most of the literature data suggest that 100% of the isolates tested are usually sensitive to ceftiofur [6,45,47,48,54]. To tilmicosin, 95.2% of the isolates were sensitive, which is in agreement with the results reported in the literature [6,45,47,48,53], while to tiamulin, 97.7% of the isolates were sensitive, which is higher than that reported by Vilaró et al. (60.8%) [48]. For amoxicillin (100.0% of isolates) and for doxycycline (69.2% of isolates), we found a higher sensitivity than Vilaró et al. (96.2% and 51.5%, respectively) [48]. For sulfamethoxazole-trimethoprim, El Garch et al. [6] and Oh et al. [53] reported a sensitivity above 90% for the tested isolates, whereas Vilaró et al. [48] reported a sensitivity of only 74.7%. In contrast, the isolates collected by us showed 100% resistance to this substance.
For tylosin, our MIC90 value was 32 µg/mL, which is in agreement with that reported by Oh et al. [53] and lower than that reported by El Garch et al. [6] (64 µg/mL). In relation to lincomycin, the MIC90 value for the isolates collected by us was 32 µg/mL, which is the same as described by El Garch et al. [6], but higher than that published by Cuevas et al. (16 µg/mL) [54].
These suggest that in the case of P. multocida infection, all isolates will show sensitivity to ceftiofur and tulathromycin, similar to that of A. pleuropneumoniae infection, as well as to amoxicillin, enrofloxacin, and florfenicol. Approximate sensitivities were also observed for tilmicosin and tiamulin, which are higher for the latter agent than previously reported in the literature. Doxycycline was only effective in half of the isolates, so its empirical use should be avoided, while in the national context, the combination sulfamethoxazole-trimethoprim showed complete resistance to the isolates we tested, so its use should only be considered after a sensitivity study and only if the results are favourable.

3.3. Susceptibility of Streptococcus suis Isolates

In our study, 100% of S. suis isolates were susceptible to ceftiofur, which is in agreement with the data published in the literature [6,8,45,47,55,56,57], but it is worth noting that in most cases, researchers have already reported a few percent resistance, compared to A. pleuropneumoniae and P. multocida isolates, where 100% of isolates were sensitive in most published results. In the case of enrofloxacin and florfenicol, only 82.9% and 75.4% of our isolates were sensitive, respectively, which is lower than that reported in the literature. A sensitivity of over 90% of isolates for florfenicol and over 95% for enrofloxacin has been previously described by researchers [6,8,45,47,55,56,57]. For sulfamethoxazole-trimethoprim, in most cases more than 90% of the isolates were sensitive [8,55,57], but in the study by Hernandez et al., only 79% of the isolates were sensitive [56]. In contrast, 94.3% of the isolates we studied were resistant to potentiated sulfonamide.
In the case of amoxicillin, the MIC90 of the isolates we tested was 4 µg/mL, whereas previously in the literature a value of 0.06 µg/mL or less was described [6,56]. Doxycycline also had a higher MIC90 (32 µg/mL) than previously described (16 µg/mL) [56]. The MIC90 value obtained for tylosin, tilmicosin, tulathromycin, and lincomycin was consistently 128 µg/mL, which is in agreement with results published by others [6,8,45,47,55,56,57], but the MIC90 value obtained for tiamulin (128 µg/mL) was higher than previously described (16 µg/mL and 32 µg/mL) [6,56].
In conclusion, ceftiofur will be the best choice against S. suis isolates in the national context, while enrofloxacin and florfenicol, which have shown excellent efficacy in the literature, show more moderate efficacy among the national isolates. In the case of sulfamethoxazole-trimethoprim, outstanding resistance among national isolates was observed, and this antibacterial agent can only be used after sensitivity testing.

4. Materials and Methods

4.1. Laboratory Participants and Isolate Characterisation

From clinical cases collected in Hungary between 2018 and 2021, isolates of A. pleuropneumoniae, P. multocida, and S. suis were obtained from the Department of Epidemiology and Microbiology, University of Veterinary Medicine Budapest, and SCG Diagnostics Ltd. (East Hartford, CT, USA).
The isolates were collected and processed continuously throughout the study. Identification to species level was carried out based on their culture, morphological characteristics, and biochemical characteristics using commercially available kits (such as API Microbial Identification Kits, bioMerieux, Durham, NC, USA). Each isolate was stored in a mixture of 800 µL of tryptone soy broth (PharmaBio® Tryptone Soy Broth, Biolab Zrt., Budapest, Hungary) and 200 µL of sterile glycerol (Glycerol 87% P.A., Lach-Ner, Ltd., Neratovice, Czech Republic) at −80 °C until antimicrobial susceptibility testing was performed.

4.2. Determination of Minimal Inhibitory Concentration Values

The in vitro susceptibility tests were performed at the Department of Pharmacology and Toxicology, University of Veterinary Medicine Budapest. All MICs were performed in tryptone soy broth (PharmaBio® Triptone Soy Broth, Biolab Zrt., Budapest, Hungary), and for A. pleuropneumoniae strain I, NAD (β NAD, Biolab Zrt., Budapest, Hungary) supplementation was used, following the Clinical and Laboratory Standards Institute (CLSI) specifications, so that our results are reproducible and internationally comparable with those of other laboratories. For each isolate, the final concentration of bacteria in the broth dilution was 5 × 105 colony-forming units per mL (CFU/mL). Soup dilutions were performed on 96-well microplates (96-well BRANDplates—F—pureGrade S, VWR International, Radnor, PA, USA). The 96-well microplate was used to prepare a two-based dilution series of the following antibacterial agents: amoxicillin, ceftiofur, cefquinome, oxytetracycline, doxycycline, tylosin, tilmicosin, tylvalosin, tulathromycin, lincomycin, tiamulin, florfenicol, colistin, enrofloxacin, and sulfamethoxazole-trimethoprim. The concentration range of antibacterial agents was selected based on quality control principles and clinical limits [7,41].

4.3. Number of Isolates Tested per Antibiotic

In this study, we tested the susceptibility of 164 clinical isolates of A. pleuropneumoniae, 65 clinical isolates of P. multocida, and 118 clinical isolates of S. suis, for a total of 15 substances. The number of isolates tested per agent is summarised in Table 8.

4.4. Data Analysis

MIC50 and MIC90 values were determined for all clinical isolates. Where possible, these values were compared with the clinical breakpoints and epidemiological cut-off values set by CLSI and EUCAST. The percentage of the number of susceptible and resistant strains expressed as a percentage was determined (Table 1 and Table 3, Table 4, Table 5, Table 6 and Table 7).
Multidrug-resistant bacteria were defined as having acquired non-susceptibility to at least one agent in three or more antimicrobial categories [58]. For the A. pleuropneumoniae isolates, AMR profiles of the MDR bacteria were performed against those agents for which CLSI clinical breakpoints were available [41] (Table 2, Figure 1). For P. multocida and S. suis, CLSI breakpoints were available for only a few antimicrobial agents, and outstanding efficacy was observed against the isolates for these agents, so AMR profiling was not feasible.

5. Conclusions

To summarise the results of our study, ceftiofur will be the most effective antibacterial agent, showing maximum efficacy in most cases against A. pleuropneumoniae, P. multocida, and S. suis isolates. Florfenicol, tulathromycin, and tilmicosin can be highly effective against both A. pleuropneumoniae and P. multocida infections. For P. multocida isolates, amoxicillin, enrofloxacin, and tiamulin have also shown high efficacy, whereas for A. pleuropneumoniae isolates, these agents show more moderate efficacy. Tetracyclines showed only moderate sensitivity against both A. pleuropneumoniae and P. multocida isolates. Enrofloxacin and florfenicol also showed only moderate sensitivity against S. suis isolates. The national isolates showed outstanding resistance to the combination sulfamethoxazole-trimethoprim for all three bacteria. However, the high level of resistance to cefquinome in A. pleuropneumoniae strains, which is of major public health importance, should be highlighted.

Author Contributions

Conceptualisation, Z.S., P.M., R.S. and Á.J.; methodology, Z.S., Á.K., L.M. and I.B.; software, Z.S.; validation, Z.S. and Á.K.; formal analysis, Z.S., P.M. and R.S.; investigation, Z.S., P.M., R.S. and Á.K.; resources, Z.S., P.M. and R.S.; data curation, Z.S.; writing—original draft preparation, Z.S., P.M. and R.S.; writing—review and editing, Z.S. and Á.J.; visualisation, Z.S. and P.M.; supervision, Á.J.; project administration, Z.S., P.M. and R.S.; funding acquisition, Á.J. All authors have read and agreed to the published version of the manuscript.

Funding

Project no. RRF-2.3.1-21-2022-00001 has been implemented with the support provided by the Recovery and Resilience Facility (RRF), financed under the National Recovery Fund budget estimate, RRF-2.3.1-21 funding scheme.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

The authors would like to give special thanks to Éva Borbás, Kata Balogh, and Gergely Nagy for their professional assistance.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Petri, F.A.M.; Ferreira, G.C.; Arruda, L.P.; Malcher, C.S.; Storino, G.Y.; Almeida, H.M.d.S.; Sonalio, K.; Silva, D.G.D.; Oliveira, L.G.D. Associations between Pleurisy and the Main Bacterial Pathogens of the Porcine Respiratory Diseases Complex (PRDC). Animals 2023, 13, 1493. [Google Scholar] [CrossRef]
  2. Thacker, E.L. Immunology of the Porcine Respiratory Disease Complex. Vet. Clin. N. Am. Food Anim. Pract. 2001, 17, 551–565. [Google Scholar] [CrossRef] [PubMed]
  3. Chae, C. Porcine Respiratory Disease Complex: Interaction of Vaccination and Porcine Circovirus Type 2, Porcine Reproductive and Respiratory Syndrome Virus, and Mycoplasma hyopneumoniae. Vet. J. Lond. Engl. 1997 2016, 212, 1–6. [Google Scholar] [CrossRef] [PubMed]
  4. Sargeant, J.M.; Bergevin, M.D.; Churchill, K.; Dawkins, K.; Deb, B.; Dunn, J.; Hu, D.; Moody, C.; O’Connor, A.M.; O’Sullivan, T.L.; et al. A Systematic Review of the Efficacy of Antibiotics for the Prevention of Swine Respiratory Disease. Anim. Health Res. Rev. 2019, 20, 291–304. [Google Scholar] [CrossRef] [Green Version]
  5. Saade, G.; Deblanc, C.; Bougon, J.; Marois-Créhan, C.; Fablet, C.; Auray, G.; Belloc, C.; Leblanc-Maridor, M.; Gagnon, C.A.; Zhu, J.; et al. Coinfections and Their Molecular Consequences in the Porcine Respiratory Tract. Vet. Res. 2020, 51, 80. [Google Scholar] [CrossRef]
  6. El Garch, F.; de Jong, A.; Simjee, S.; Moyaert, H.; Klein, U.; Ludwig, C.; Marion, H.; Haag-Diergarten, S.; Richard-Mazet, A.; Thomas, V.; et al. Monitoring of Antimicrobial Susceptibility of Respiratory Tract Pathogens Isolated from Diseased Cattle and Pigs across Europe, 2009–2012: VetPath Results. Vet. Microbiol. 2016, 194, 11–22. [Google Scholar] [CrossRef] [PubMed]
  7. Antimicrobial Wild Type Distributions of Microorganisms, EUCAST. Available online: https://mic.eucast.org/search/?search%5Bmethod%5D=mic&search%5Bantibiotic%5D=-1&search%5Bspecies%5D=-1&search%5Bdisk_content%5D=-1&search%5Blimit%5D=50 (accessed on 17 April 2023).
  8. Holmer, I.; Salomonsen, C.M.; Jorsal, S.E.; Astrup, L.B.; Jensen, V.F.; Høg, B.B.; Pedersen, K. Antibiotic Resistance in Porcine Pathogenic Bacteria and Relation to Antibiotic Usage. BMC Vet. Res. 2019, 15, 449. [Google Scholar] [CrossRef] [Green Version]
  9. Mader, R.; Muñoz Madero, C.; Aasmäe, B.; Bourély, C.; Broens, E.M.; Busani, L.; Callens, B.; Collineau, L.; Crespo-Robledo, P.; Damborg, P.; et al. Review and Analysis of National Monitoring Systems for Antimicrobial Resistance in Animal Bacterial Pathogens in Europe: A Basis for the Development of the European Antimicrobial Resistance Surveillance Network in Veterinary Medicine (EARS-Vet). Front. Microbiol. 2022, 13, 838490. [Google Scholar] [CrossRef]
  10. Toutain, P.-L.; Pelligand, L.; Lees, P.; Bousquet-Mélou, A.; Ferran, A.A.; Turnidge, J.D. The Pharmacokinetic/Pharmacodynamic Paradigm for Antimicrobial Drugs in Veterinary Medicine: Recent Advances and Critical Appraisal. J. Vet. Pharmacol. Ther. 2021, 44, 172–200. [Google Scholar] [CrossRef]
  11. Kowalska-Krochmal, B.; Dudek-Wicher, R. The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance. Pathogens 2021, 10, 165. [Google Scholar] [CrossRef]
  12. Kardos, G.; Sárközi, R.; Laczkó, L.; Marton, S.; Makrai, L.; Bányai, K.; Fodor, L. Genetic Diversity of Actinobacillus Pleuropneumoniae Serovars in Hungary. Vet. Sci. 2022, 9, 511. [Google Scholar] [CrossRef] [PubMed]
  13. Burch, D.G.S.; Sperling, D. Amoxicillin—Current Use in Swine Medicine. J. Vet. Pharmacol. Ther. 2018, 41, 356–368. [Google Scholar] [CrossRef] [Green Version]
  14. European Medicines Agency Categorisation of Antibiotics in the European Union 2019. Available online: https://www.ema.europa.eu/en/documents/report/categorisation-antibiotics-european-union-answer-request-european-commission-updating-scientific_en.pdf (accessed on 17 April 2023).
  15. Chander, Y.; Oliveira, S.; Goyal, S.M. Characterisation of Ceftiofur Resistance in Swine Bacterial Pathogens. Vet. J. 2011, 187, 139–141. [Google Scholar] [CrossRef] [PubMed]
  16. Zhang, L.; Wu, X.; Huang, Z.; Zhang, N.; Wu, Y.; Cai, Q.; Shen, X.; Ding, H. Pharmacokinetic/Pharmacodynamic Assessment of Cefquinome against Actinobacillus Pleuropneumoniae in a Piglet Tissue Cage Infection Model. Vet. Microbiol. 2018, 219, 100–106. [Google Scholar] [CrossRef] [PubMed]
  17. Zhang, L.; Xie, H.; Wang, H.; Ding, H.; Zhang, G.; Hu, J. Kill Rate and Evaluation of Ex Vivo PK/PD Integration of Cefquinome against Actinobacillus Pleuropneumoniae. Front. Vet. Sci. 2021, 8, 751957. [Google Scholar] [CrossRef]
  18. Tóth, A.G.; Csabai, I.; Maróti, G.; Jerzsele, Á.; Dubecz, A.; Patai, Á.V.; Judge, M.F.; Nagy, S.Á.; Makrai, L.; Bányai, K.; et al. A Glimpse of Antimicrobial Resistance Gene Diversity in Kefir and Yoghurt. Sci. Rep. 2020, 10, 22458. [Google Scholar] [CrossRef]
  19. Cheng, D.; Feng, Y.; Liu, Y.; Xue, J.; Li, Z. Dynamics of Oxytetracycline, Sulfamerazine, and Ciprofloxacin and Related Antibiotic Resistance Genes during Swine Manure Composting. J. Environ. Manag. 2019, 230, 102–109. [Google Scholar] [CrossRef]
  20. Mazurek, J.; Bok, E.; Stosik, M.; Baldy-Chudzik, K. Antimicrobial Resistance in Commensal Escherichia Coli from Pigs during Metaphylactic Trimethoprim and Sulfamethoxazole Treatment and in the Post-Exposure Period. Int. J. Environ. Res. Public Health 2015, 12, 2150–2163. [Google Scholar] [CrossRef]
  21. Yang, F.; Liu, H.W.; Li, M.; Ding, H.Z.; Huang, X.H.; Zeng, Z.L. Use of a Monte Carlo Analysis within a Physiologically Based Pharmacokinetic Model to Predict Doxycycline Residue Withdrawal Time in Edible Tissues in Swine. Food Addit. Contam. Part A 2012, 29, 73–84. [Google Scholar] [CrossRef]
  22. Dorey, L.; Pelligand, L.; Cheng, Z.; Lees, P. Pharmacokinetic/Pharmacodynamic Integration and Modelling of Florfenicol for the Pig Pneumonia Pathogens Actinobacillus Pleuropneumoniae and Pasteurella Multocida. PLoS ONE 2017, 12, e0177568. [Google Scholar] [CrossRef] [Green Version]
  23. Xiong, J.; Zhu, Q.; Yang, S.; Zhao, Y.; Cui, L.; Zhuang, F.; Qiu, Y.; Cao, J. Comparison of Pharmacokinetics of Tilmicosin in Healthy Pigs and Pigs Experimentally Infected with Actinobacillus Pleuropneumoniae. N. Z. Vet. J. 2019, 67, 257–263. [Google Scholar] [CrossRef] [PubMed]
  24. Huang, L.; Zhang, H.; Li, M.; Ahmad, I.; Wang, Y.; Yuan, Z. Pharmacokinetic-Pharmacodynamic Modeling of Tylosin against Streptococcus suis in Pigs. BMC Vet. Res. 2018, 14, 319. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Zhou, Q.; Zhang, G.; Wang, Q.; Liu, W.; Huang, Y.; Yu, P.; Li, Y.; Ding, H.; Fang, B. Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella Multocida in a Porcine Tissue Cage Model. Front. Pharmacol. 2017, 8, 392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Bladek, T.; Posyniak, A.; Jablonski, A.; Gajda, A. Pharmacokinetics of Tulathromycin in Edible Tissues of Healthy and Experimentally Infected Pigs with Actinobacillus Pleuropneumoniae. Food Addit. Contam. Part A 2015, 32, 1823–1832. [Google Scholar] [CrossRef]
  27. Nielsen, P.; Gyrd-Hansen, N. Bioavailability of Spiramycin and Lincomycin after Oral Administration to Fed and Fasted Pigs. J. Vet. Pharmacol. Ther. 1998, 21, 251–256. [Google Scholar] [CrossRef]
  28. Pallarés, F.J.; Lasa, C.; Roozen, M.; Ramis, G. Use of Tylvalosin in the Control of Porcine Enzootic Pneumonia. Vet. Rec. Open 2015, 2, e000079. [Google Scholar] [CrossRef] [Green Version]
  29. Albert, E.; Sipos, R.; Perreten, V.; Tóth, Á.; Ungvári, E.; Papp, M.; Dán, Á.; Biksi, I. High Prevalence of Livestock-Associated Methicillin-Resistant Staphylococcus aureus in Hungarian Pig Farms and Genomic Evidence for the Spillover of the Pathogen to Humans. Transbound. Emerg. Dis. 2023, 2023, 5540019. [Google Scholar] [CrossRef]
  30. Somogyi, Z.; Mag, P.; Kovács, D.; Kerek, Á.; Szabó, P.; Makrai, L.; Jerzsele, Á. Synovial and Systemic Pharmacokinetics of Florfenicol and PK/PD Integration against Streptococcus suis in Pigs. Pharmaceutics 2022, 14, 109. [Google Scholar] [CrossRef]
  31. Somogyi, Z.; Mag, P.; Simon, R.; Kerek, Á.; Szabó, P.; Albert, E.; Biksi, I.; Jerzsele, Á. Pharmacokinetics and Pharmacodynamics of Florfenicol in Plasma and Synovial Fluid of Pigs at a Dose of 30 Mg/Kgbw Following Intramuscular Administration. Antibiotics 2023, 12, 758. [Google Scholar] [CrossRef]
  32. Grégoire, N.; Aranzana-Climent, V.; Magréault, S.; Marchand, S.; Couet, W. Clinical Pharmacokinetics and Pharmacodynamics of Colistin. Clin. Pharmacokinet. 2017, 56, 1441–1460. [Google Scholar] [CrossRef]
  33. Rhouma, M.; Beaudry, F.; Thériault, W.; Letellier, A. Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives. Front. Microbiol. 2016, 7, 1789. [Google Scholar] [CrossRef] [Green Version]
  34. Rhouma, M.; Beaudry, F.; Thériault, W.; Bergeron, N.; Beauchamp, G.; Laurent-Lewandowski, S.; Fairbrother, J.M.; Letellier, A. In Vivo Therapeutic Efficacy and Pharmacokinetics of Colistin Sulfate in an Experimental Model of Enterotoxigenic Escherichia Coli Infection in Weaned Pigs. Vet. Res. 2016, 47, 58. [Google Scholar] [CrossRef] [Green Version]
  35. Chen, T.; Xie, G.; Mi, J.; Wen, X.; Cao, Z.; Ma, B.; Zou, Y.; Zhang, N.; Wang, Y.; Liao, X.; et al. Recovery of the Structure and Function of the Pig Manure Bacterial Community after Enrofloxacin Exposure. Microbiol. Spectr. 2022, 10, e02004-21. [Google Scholar] [CrossRef]
  36. De Smet, J.; Boyen, F.; Croubels, S.; Rasschaert, G.; Haesebrouck, F.; Temmerman, R.; Rutjens, S.; De Backer, P.; Devreese, M. The Impact of Therapeutic-Dose Induced Intestinal Enrofloxacin Concentrations in Healthy Pigs on Fecal Escherichia coli Populations. BMC Vet. Res. 2020, 16, 382. [Google Scholar] [CrossRef]
  37. González-Fandos, E.; Martínez-Laorden, A.; Abad-Fau, A.; Sevilla, E.; Bolea, R.; Serrano, M.J.; Mitjana, O.; Bonastre, C.; Laborda, A.; Falceto, M.V.; et al. Effect of Intramuscularly Administered Oxytetracycline or Enrofloxacin on Vancomycin-Resistant Enterococci, Extended Spectrum Beta-Lactamase- and Carbapenemase-Producing Enterobacteriaceae in Pigs. Animals 2022, 12, 622. [Google Scholar] [CrossRef]
  38. Kaspersen, H.; Urdahl, A.M.; Grøntvedt, C.A.; Gulliksen, S.M.; Tesfamichael, B.; Slettemeås, J.S.; Norström, M.; Sekse, C. Actinobacillus pleuropneumoniae Eradication with Enrofloxacin May Lead to Dissemination and Long-Term Persistence of Quinolone Resistant Escherichia Coli in Pig Herds. Antibiotics 2020, 9, 910. [Google Scholar] [CrossRef]
  39. Matamoros, V.; Casas, M.E.; Pastor, E.; Tadić, Đ.; Cañameras, N.; Carazo, N.; Bayona, J.M. Effects of Tetracycline, Sulfonamide, Fluoroquinolone, and Lincosamide Load in Pig Slurry on Lettuce: Agricultural and Human Health Implications. Environ. Res. 2022, 215, 114237. [Google Scholar] [CrossRef]
  40. Yang, B.; Li, X.D.; Chen, X.; Hong, J.; Liu, C.; Zheng, J.P.; Ou, Z.Y.; Yu, D.J. PK/PD Modelling of Enrofloxacin against Glaesserella parasuis Infection in Pigs. J. Vet. Pharmacol. Ther. 2022, 45, 291–300. [Google Scholar] [CrossRef]
  41. CLSI. Performance Standards for Antimicrobial Disk Dilution Susceptibility Tests for Bacteria Isolated from Animals, 5th ed.; CLSI Supplement VET01S; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2020. [Google Scholar]
  42. 128/2009. (X. 6.) FVM Rendelet az Állatgyógyászati Termékekről. Available online: https://net.jogtar.hu/jogszabaly?docid=A0900128.FVM&searchUrl=%2Fgyorskereso%3Fkeyword%3Dfvm%2520128%2F2009 (accessed on 17 April 2023).
  43. Committee, S. Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Veterinary Medicinal Products. Off. J. L 2001, 311, 1–66. [Google Scholar]
  44. European Union. Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on Veterinary Medicinal Products and Repealing Directive 2001/82/EC (Text with EEA Relevance). Off. J. Eur. Union 2018, 4, 44. [Google Scholar]
  45. Portis, E. Antimicrobial Susceptibility of Porcine Pasteurella multocida, Streptococcus suis, and Actinobacillus pleuropneumoniae from the United States and Canada, 2001 to 2010. J. Swine Health Prod. 2013, 21, 30–41. [Google Scholar]
  46. Kucerova, Z.; Hradecka, H.; Nechvatalova, K.; Nedbalcova, K. Antimicrobial Susceptibility of Actinobacillus pleuropneumoniae Isolates from Clinical Outbreaks of Porcine Respiratory Diseases. Vet. Microbiol. 2011, 150, 203–206. [Google Scholar] [CrossRef] [PubMed]
  47. Sweeney, M.T. Antimicrobial Susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida, Streptococcus suis, and Bordetella bronchiseptica Isolated from Pigs in the United States and Canada, 2011 to 2015. J. Swine Health Prod. 2017, 25, 106–120. [Google Scholar]
  48. Vilaró, A.; Novell, E.; Enrique-Tarancón, V.; Balielles, J.; Vilalta, C.; Martinez, S.; Fraile Sauce, L.J. Antimicrobial Susceptibility Pattern of Porcine Respiratory Bacteria in Spain. Antibiotics 2020, 9, 402. [Google Scholar] [CrossRef]
  49. Gutiérrez-Martín, C.B.; Blanco, N.G.D.; Blanco, M.; Navas, J.; Rodríguez-Ferri, E.F. Changes in Antimicrobial Susceptibility of Actinobacillus pleuropneumoniae Isolated from Pigs in Spain during the Last Decade. Vet. Microbiol. 2006, 115, 218–222. [Google Scholar] [CrossRef] [PubMed]
  50. Yuan, Y.; An, B.; Xie, S.; Qu, W.; Hao, H.; Huang, L.; Luo, W.; Liang, J.; Peng, D. The Dose Regimen Formulation of Doxycycline Hydrochloride and Florfenicol Injection Based on Ex Vivo Pharmacokinetic-Pharmacodynamic Modeling against the Actinobacillus pleuropneumoniae in Pigs. Anim. Dis. 2023, 3, 3. [Google Scholar] [CrossRef]
  51. Chang, C.-F.; Chang, L.-C.; Chang, Y.-F.; Chen, M.; Chiang, T.-S. Antimicrobial Susceptibility of Actinobacillus pleuropneumoniae, Escherichia coli, and Salmonella choleraesuis Recovered from Taiwanese Swine. J. Vet. Diagn. Investig. 2002, 14, 153–157. [Google Scholar] [CrossRef] [Green Version]
  52. Matter, D.; Rossano, A.; Limat, S.; Vorlet-Fawer, L.; Brodard, I.; Perreten, V. Antimicrobial Resistance Profile of Actinobacillus pleuropneumoniae and Actinobacillus porcitonsillarum. Vet. Microbiol. 2007, 122, 146–156. [Google Scholar] [CrossRef]
  53. Oh, Y.-H.; Moon, D.-C.; Lee, Y.J.; Hyun, B.-H.; Lim, S.-K. Antimicrobial Resistance of Pasteurella Multocida Strains Isolated from Pigs between 2010 and 2016. Vet. Rec. Open 2018, 5, e000293. [Google Scholar] [CrossRef] [Green Version]
  54. Cuevas, I.; Carbonero, A.; Cano, D.; García-Bocanegra, I.; Amaro, M.Á.; Borge, C. Antimicrobial Resistance of Pasteurella Multocida Type B Isolates Associated with Acute Septicemia in Pigs and Cattle in Spain. BMC Vet. Res. 2020, 16, 222. [Google Scholar] [CrossRef]
  55. Wisselink, H.J.; Veldman, K.T.; Van den Eede, C.; Salmon, S.A.; Mevius, D.J. Quantitative Susceptibility of Streptococcus suis Strains Isolated from Diseased Pigs in Seven European Countries to Antimicrobial Agents Licenced in Veterinary Medicine. Vet. Microbiol. 2006, 113, 73–82. [Google Scholar] [CrossRef] [PubMed]
  56. Hernandez-Garcia, J.; Wang, J.; Restif, O.; Holmes, M.A.; Mather, A.E.; Weinert, L.A.; Wileman, T.M.; Thomson, J.R.; Langford, P.R.; Wren, B.W.; et al. Patterns of Antimicrobial Resistance in Streptococcus Suis Isolates from Pigs with or without Streptococcal Disease in England between 2009 and 2014. Vet. Microbiol. 2017, 207, 117–124. [Google Scholar] [CrossRef] [PubMed]
  57. van Hout, J.; Heuvelink, A.; Gonggrijp, M. Monitoring of Antimicrobial Susceptibility of Streptococcus Suis in the Netherlands, 2013–2015. Vet. Microbiol. 2016, 194, 5–10. [Google Scholar] [CrossRef]
  58. Magiorakos, A.-P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Antibiotics 12 01298 g001
Figure 1. Percentage distribution of isolates according to the number of antimicrobials to which they show resistance.
Figure 1. Percentage distribution of isolates according to the number of antimicrobials to which they show resistance.
Antibiotics 12 01298 g001
Table 1. Distribution of MIC values for the clinical isolates of Actinobacillus pleuropneumoniae tested and the MIC50 and MIC90 values. The top row shows the number of pieces, and the bottom row shows the percentage distribution per substance. The red line indicates concentrations that are already resistant to the antibacterial agent, based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Table 1. Distribution of MIC values for the clinical isolates of Actinobacillus pleuropneumoniae tested and the MIC50 and MIC90 values. The top row shows the number of pieces, and the bottom row shows the percentage distribution per substance. The red line indicates concentrations that are already resistant to the antibacterial agent, based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Antibacterial AgentsIsolates Tested (pcs)Breakpoints (µg/mL)Distribution of Bacterial Strains (pcs and %) by Dilution Series (µg/mL)MIC50 (µg/mL)MIC90 (µg/mL)
12864321684210.50.250.1250.060.030.015
Amoxicillin164≥2 * 3618131 8948131314 0.2564
22.011.00.61.80.6 4.95.529.37.97.98.5
Ceftiofur144≥8 * 622 3142432610.030.125
4.11.41.4 2.19.716.722.242.4
Cefquinome41≥0.03 ** 2236151030.060.25
4.94.97.314.636.624.47.3
Oxytetracycline45≥2 *4182 1 21017 3264
8.940.04.4 2.2 4.422.22.215.6
Doxycycline109- 18233283017836 116
0.97.321.12.81.87.327.515.67.32.85.5
Tylosin78-6173648 11 23 3264
7.721.846.25.110.3 1.31.3 2.63.8
Tilmicosin138≥32 *23134320192922212 48
1.42.20.72.231.214.513.821.01.41.41.48.7
Tylvalosin58-1377 11 24 6464
1.863.812.1 1.71.7 3.46.9
Tulathromycin139≥128 * 1123188482327224 0.516
0.70.716.512.95.82.95.816.519.41.417.3
Lincomycin70-52713154 6 3264
7.138.618.621.45.7 8.6
Tiamulin112≥32 *96182314141091 26 864
8.05.416.120.512.512.58.98.00.90.01.85.4
Florfenicol164≥8 * 1 1192154521366 14
0.6 0.611.612.832.931.70.61.83.73.7
Colistin88- 3 8 3 23510.0151
3.4 9.1 3.4 26.158.0
Enrofloxacin141≥1 *31 271125252212294014
2.10.7 1.45.07.817.717.71.41.48.51.46.428.4
Sulfamethoxazole/
Trimethoprim+		61≥0.125 **53 2712135314 6 264
8.24.9 3.311.519.721.38.24.91.66.6 9.8
Table 2. Percentage of susceptibility of clinical isolates of Actinobacillus pleuropneumoniae to the antibacterial agents tested, based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Table 2. Percentage of susceptibility of clinical isolates of Actinobacillus pleuropneumoniae to the antibacterial agents tested, based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Antimicrobial AgentsStrains Tested (pcs)Breakpoints (µg/mL)Sensitive (%)Resistant (%)
Amoxicillin164≥2 *64.036.0
Ceftiofur144≥8 *100.00.0
Cefquinome41≥0.03 **7.392.7
Oxytetracycline45≥2 *44.455.6
Tilmicosin138≥32 *95.74.3
Tulathromycin139≥128 *100.00.0
Tiamulin112≥32 *70.529.5
Florfenicol164≥8 *98.81.2
Enrofloxacin141≥1 *47.552.5
Sulfamethoxazole/Trimethoprim+61≥0.125 **9.890.8
Table 3. MDR profiles detected in A. pleuropneumoniae isolates.
Table 3. MDR profiles detected in A. pleuropneumoniae isolates.
Profile NumberNumber of IsolatesMDR Profile *
112AM, TIA, ENR
28AM, OTC, TIA
32AM, OTC, TIA, FLO
41AM, OTC, TILM
51OTC, TILM, TIA
* AM = amoxicillin, TIA = tiamulin, ENR = enrofloxacin, OTC = oxytetracycline, FLO = florfenicol, and TILM = tilmicosin.
Table 4. Distribution of MIC values for the Pasteurella multocida clinical isolates tested and the MIC50 and MIC90 values. The top row shows the number of pieces, and the bottom row shows the percentage distribution per substance. The red line indicates concentrations that are already resistant to the antibacterial agent, based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Table 4. Distribution of MIC values for the Pasteurella multocida clinical isolates tested and the MIC50 and MIC90 values. The top row shows the number of pieces, and the bottom row shows the percentage distribution per substance. The red line indicates concentrations that are already resistant to the antibacterial agent, based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Antibacterial AgentsIsolates Tested (pcs)Breakpoints (µg/mL)Distribution of Bacterial Strains (pcs and %) by Dilution Series (µg/mL)MIC50 (µg/mL)MIC90 (µg/mL)
25612864321684210.50.250.1250.060.030.015
Amoxicillin65≥2 * 1315214102 0.251
20.023.132.36.215.43.1
Ceftiofur63≥8 * 1 2124714320.0150.125
1.6 3.21.63.26.311.122.250.8
Doxycycline65≥1 ** 2 1359197613 0.52
3.1 1.54.67.713.829.210.89.220.0
Tylosin29- 211133 1632
6.937.944.810.3
Tilmicosin42≥32 * 2122118124 18
4.82.44.84.826.219.028.69.5
Tulathromycin59≥64 * 1 1 1591723 20.1250.5
1.7 1.7 1.78.515.328.839.0 3.4
Lincomycin19- 2661 22 1632
10.531.631.65.3 10.510.5
Tiamulin44≥64 ** 12132251 816
2.34.529.550.011.42.3
Florfenicol65≥8 * 2211301613 0.51
3.13.116.946.224.61.54.6
Colistin25- 1 81060.030.06
4 324024
Enrofloxacin41≥1 * 912200.030.06
22.029.348.8
Sulfamethoxazole/
Trimethoprim+		54≥0.125 **32 95410192 432
5.63.7 16.79.37.418.535.23.7
Table 5. Percentage of susceptibility of clinical isolates of Pasteurella multocida to the antibacterial agents tested based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Table 5. Percentage of susceptibility of clinical isolates of Pasteurella multocida to the antibacterial agents tested based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Antimicrobial AgentsStrains Tested (pcs)Breakpoints (µg/mL)Sensitive (%)Resistant (%)
Amoxicillin65≥2 *100.00.0
Ceftiofur63≥8 *98.41.6
Doxycycline65≥1 **69.230.8
Tilmicosin42≥32 *95.24.8
Tulathromycin59≥64 *100.00.0
Tiamulin44≥64 **97.72.3
Florfenicol65≥8 *100.00.0
Enrofloxacin41≥1 *100.00.0
Sulfamethoxazole/Trimethoprim+54≥0.125 **0.0100.0
Table 6. Distribution of MIC values for the Streptococcus suis clinical isolates tested and the MIC50 and MIC90 values. The top row shows the number of pieces, and the bottom row shows the percentage distribution per substance. The red line indicates concentrations that are already resistant to the antibacterial agent, based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Table 6. Distribution of MIC values for the Streptococcus suis clinical isolates tested and the MIC50 and MIC90 values. The top row shows the number of pieces, and the bottom row shows the percentage distribution per substance. The red line indicates concentrations that are already resistant to the antibacterial agent, based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Antibacterial AgentsIsolates Tested (pcs)Breakpoints (µg/mL)Distribution of Bacterial Strains (pcs and %) by Dilution Series (µg/mL)MIC50 (µg/mL)MIC90 (µg/mL)
25612864321684210.50.250.1250.060.030.015
Amoxicillin116- 42412 434123743 0.064
3.41.73.40.91.7 3.42.63.410.331.937.1
Ceftiofur117≥8 * 23841031317570.031
1.72.66.83.48.52.611.114.548.7
Doxycycline100- 32418687254815 832
32418687254815
Tylosin41- 15.0 12.0 2.0 3.02.01.0 6.0 32128
36.6 29.3 4.9 7.34.92.4 14.6
Tilmicosin86- 212117314163747 8128
24.42.312.88.13.51.24.718.63.58.14.78.1
Tylvalosin89- 171 14647358416222128
19.11.1 15.76.74.57.93.45.69.04.518.02.22.2
Lincomycin40- 17342 24 8 32128
42.57.510.05.0 5.010.0 20.0
Tiamulin33- 871161 14112 16128
24.221.23.03.018.23.0 3.012.13.03.06.1
Florfenicol118≥8 * 8 41724389535 5 28
6.8 3.414.420.332.27.64.22.54.2 4.2
Enrofloxacin70≥2 * 451212127116460.58
5.77.11.42.917.117.110.015.78.65.78.6
Sulfamethoxazole/
Trimethoprim +		105≥0.25 **15172910131832916 16256
14.316.21.98.69.512.417.12.91.98.61.05.7
Table 7. Percentage of susceptibility of clinical isolates of Streptococcus suis to the antibacterial agents tested, based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Table 7. Percentage of susceptibility of clinical isolates of Streptococcus suis to the antibacterial agents tested, based on CLSI (*) and EUCAST (**) recommendations. +MIC values are relative to the trimethoprim component in the 20:1 sulfamethoxazole/trimethoprim combination.
Antimicrobial AgentsStrains Tested (pcs)Breakpoints (µg/mL)Sensitive (%)Resistant (%)
Ceftiofur117≥8 *100.00.0
Florfenicol118≥8 *75.424.6
Enrofloxacin105≥2 *82.917.1
Sulfamethoxazole/Trimethoprim+116≥0.25 **5.794.3
Table 8. Number of A. pleuropneumoniae, P. multocida, and S. suis isolates tested, by substance and in total.
Table 8. Number of A. pleuropneumoniae, P. multocida, and S. suis isolates tested, by substance and in total.
Antibacterial
Agent		A. pleuropneumoniae
(pcs)		P. multocida
(pcs)		S. suis
(pcs)
Amoxicillin16465116
Ceftiofur14463117
Cefquinome41--
Oxytetracycline45--
Doxycycline10965100
Tylosin782941
Tilmicosin1384286
Tylvalosin58--
Tulathromycin1395989
Lincomycin701940
Tiamulin1124433
Florfenicol16465118
Colistin8825-
Enrofloxacin1414170
Sulfamethoxazole:
Trimethoprim (20:1)		6154105
Total (pcs)16465118
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Somogyi, Z.; Mag, P.; Simon, R.; Kerek, Á.; Makrai, L.; Biksi, I.; Jerzsele, Á. Susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis Isolated from Pigs in Hungary between 2018 and 2021. Antibiotics 2023, 12, 1298. https://doi.org/10.3390/antibiotics12081298

AMA Style

Somogyi Z, Mag P, Simon R, Kerek Á, Makrai L, Biksi I, Jerzsele Á. Susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis Isolated from Pigs in Hungary between 2018 and 2021. Antibiotics. 2023; 12(8):1298. https://doi.org/10.3390/antibiotics12081298

Chicago/Turabian Style

Somogyi, Zoltán, Patrik Mag, Réka Simon, Ádám Kerek, László Makrai, Imre Biksi, and Ákos Jerzsele. 2023. "Susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis Isolated from Pigs in Hungary between 2018 and 2021" Antibiotics 12, no. 8: 1298. https://doi.org/10.3390/antibiotics12081298

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop